Technical Analysis for SPRB - Spruce Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Flat | Up |
| Historical SPRB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -1.14% | |
| Crossed Above 50 DMA | Bullish | -1.14% | |
| MACD Bullish Signal Line Cross | Bullish | -1.14% | |
| Up 3 Days in a Row | Strength | -1.14% | |
| 50 DMA Resistance | Bearish | 1.96% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 1% | 1 day ago | |
| Fell Below 50 DMA | 1 day ago | |
| 60 Minute Opening Range Breakout | 1 day ago | |
| 50 DMA Support | 1 day ago | |
| 20 DMA Support | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Anatomy Hyperplasia Cah Endocrine Disorders Adrenal Gland Disorders Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Anatomy Hyperplasia Cah Endocrine Disorders Adrenal Gland Disorders Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.6 |
| 52 Week Low | 15.14 |
| Average Volume | 89,896 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 23.47 |
| 20-Day Moving Average | 22.65 |
| 10-Day Moving Average | 22.19 |
| Average True Range | 2.02 |
| ADX | 16.15 |
| +DI | 16.90 |
| -DI | 20.00 |
| Chandelier Exit (Long, 3 ATRs ) | 19.31 |
| Chandelier Exit (Short, 3 ATRs ) | 25.80 |
| Upper Bollinger Band | 25.22 |
| Lower Bollinger Band | 20.08 |
| Percent B (%b) | 0.65 |
| BandWidth | 22.66 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.29 |
| MACD Histogram | 0.1079 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.45 | ||||
| Resistance 3 (R3) | 25.40 | 24.69 | 25.11 | ||
| Resistance 2 (R2) | 24.69 | 24.17 | 24.71 | 24.99 | |
| Resistance 1 (R1) | 24.05 | 23.85 | 23.70 | 24.10 | 24.88 |
| Pivot Point | 23.34 | 23.34 | 23.16 | 23.36 | 23.34 |
| Support 1 (S1) | 22.70 | 22.82 | 22.35 | 22.75 | 21.96 |
| Support 2 (S2) | 21.99 | 22.50 | 22.01 | 21.85 | |
| Support 3 (S3) | 21.35 | 21.99 | 21.73 | ||
| Support 4 (S4) | 21.40 |
